SCHEMBL26634828

SCHEMBL26634828

CCOC(=O)C(O)c1cn(C)nn1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
HIF1A Q16665 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
PTGS2 P35354 2/20 0.33
KMT2A Q03164 2/20 0.33
TP53 P04637 1/20 0.33
ALOX12 P18054 1/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
SLC5A1 P13866 2/20 0.32
SLC5A2 P31639 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22440146 0.75 KMT2A (0.35) ALDH1A1LMNASMN1; SMN2PTGS2KMT2A
SCHEMBL23376772 0.75 ALDH1A1 (0.63) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL2515677 0.71 ALDH1A1 (0.60) MAPK1ALDH1A1LMNACYP1A2SMN1; SMN2
SCHEMBL20204351 0.69
SCHEMBL19041027 0.69
SCHEMBL14084264 0.69
SCHEMBL17122470 0.69 HSD17B10 (0.45) MAPK1ALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL22367496 0.68 KMT2A (0.36) ALDH1A1SMN1; SMN2KMT2A
SCHEMBL12751699 0.67 ALDH1A1 (0.38) ALDH1A1CYP1A2CYP2C9HIF1ASMN1; SMN2
SCHEMBL16852894 0.66 CA12 (0.49) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570626-B2 Degraders and degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 US disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 US disclosed
US-11524949-B2 Degraders and Degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2022-12-13 US disclosed
US-20220251061-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2022-08-11 US disclosed
CN-111372585-A Degradants and degreddeterminants for target protein degradation C4医药公司 2020-07-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570626-B2 Degraders and degrons for targeted protein degradation ADRM1, UCHL3, USP30 MAPK1 3925/4885ALDH1A1 3506/4885LMNA 4258/4885
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION STUB1, MDM2, USP30 MAPK1 3828/4885ALDH1A1 3735/4885LMNA 2540/4885
US-20220251061-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION STUB1, MDM2, USP30 MAPK1 3828/4885ALDH1A1 3735/4885LMNA 2540/4885
US-11524949-B2 Degraders and Degrons for targeted protein degradation STUB1, MDM2, USP30 MAPK1 3828/4885ALDH1A1 3735/4885LMNA 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.